Frontier Pharma: Rheumatoid Arthritis – Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

“The Report Frontier Pharma: Rheumatoid Arthritis – Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium – the soft tissue of the joint – leading to pain, joint stiffness, and eventually deformity and disability.

With the disease affecting 0.3–1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.

Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for first-in-class innovation, which is the area most likely to produce substantial clinical advances.

Download Sample copy of this Report at :


  • Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.

  • What is the pathophysiology of RA?

  • Which products and therapeutic strategies dominate the clinical and commercial landscapes?

  • What are the most significant unmet needs within the RA market?

  • Considerable diversification from current market trends is evident within the RA pipeline.

  • Which molecular targets are most prominent within the pipeline?

  • What proportion of pipeline products are first in class?

  • Which first-in-class targets are most promising?

  • Deal values for licensing and co-development deals vary considerably.

  • How many strategic consolidations have been completed in the past decade?

  • Which types of assets attract the largest deal values?

  • Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons To Buy

This report will allow you to:

  • Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options.

  • Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market.

  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the RA pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

  • Identify first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 5

2.1 A Crowded, Competitive Market, with Significant Unmet Needs Remaining 5

2.2 Early-Stage Pipeline Offers Greatest Promise for First-in-Class Innovation 5

2.3 Cytokine and Cytokine Receptors, as well as Protein Kinases, Largely Dominate First-in-Class Pipeline Products 5

3 The Case for Innovation 6

3.1 Growing Opportunities for Biologic Products 7

3.2 Diversification of Molecular Targets 7

3.3 Innovative First-in-Class Development Remains Attractive 8

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8

3.5 Sustained Innovation 9

3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10

4.1 Disease Overview 10

4.2 Disease Symptoms 10

4.3 Epidemiology 11

4.4 Etiology 11

4.5 Pathophysiology 11

4.6 Co-morbidities and Complications 12

4.7 Diagnosis 12

4.7.1 Blood Tests 12

4.7.2 1987 Rheumatoid Arthritis Classification 13

4.7.3 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis 13

4.8 Disease Progression 13

4.9 Treatment Options and Treatment Algorithm 14

4.10 Overview of Marketed Products in Rheumatoid Arthritis 15

4.10.1 Molecule Type and Molecular Target Analysis 15

5 Assessment of Pipeline Product Innovation 17

5.1 Rheumatoid Arthritis Pipeline by Stage of Development, Molecule Type and Molecular Target 17

5.2 Comparative Distribution of Programs between the Rheumatoid Arthritis Market and Pipeline by Therapeutic Target Family 21

5.3 First-in-Class Programs Targeting Novel Molecular Targets 21

6 Signaling Network, Disease Causation and Innovation Alignment 32

6.1 Complexity of Signaling Networks in Rheumatoid Arthritis 32

6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 33

6.3 First-in-Class Matrix Assessment 33

Follow us on LinkedIn:

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074